PROCEPT BioRobotics Corp
PRCT- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001588978
In the last 90 days, PROCEPT BioRobotics Corp insiders filed 0 open-market purchases and 4 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $1.24B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:18 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $95.6M (31.0% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 25, 2025 | Feb 27, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Revenue | $308.1M | $224.5M | $136.2M | $75.0M | $34.5M |
| Cost of revenue | $111.8M | $87.4M | $65.1M | $37.9M | $18.6M |
| Gross profit | $196.2M | $137.1M | $71.0M | $37.1M | $15.9M |
| Operating expenses | $300.1M | $233.7M | $180.2M | $117.8M | $70.0M |
| Research and development | $71.3M | $62.3M | $48.4M | $29.0M | $19.0M |
| Selling, general and administrative | $228.8M | $171.4M | $131.8M | $88.8M | $51.0M |
| Operating income | -$103.9M | -$96.6M | -$109.2M | -$80.7M | -$54.2M |
| Interest expense | – | – | $4.00M | $5.18M | $5.81M |
| Income tax | $190.0K | $0 | $0 | $0 | $0 |
| Net income | -$95.6M | -$91.4M | -$105.9M | -$87.2M | -$59.9M |
| EPS, basic | $-1.72 | $-1.75 | $-2.24 | $-1.96 | $-3.63 |
| EPS, diluted | $-1.72 | $-1.75 | $-2.24 | $-1.96 | $-3.63 |
| Weighted shares, basic | 55.5M | 52.1M | 47.3M | 44.4M | 16.5M |
| Weighted shares, diluted | 55.5M | 52.1M | 47.3M | 44.4M | 16.5M |
| Margins and growth | |||||
| Gross margin | 63.7% | 61.1% | 52.2% | 49.4% | 46.0% |
| Operating margin | -33.7% | -43.0% | -80.2% | -107.6% | -157.1% |
| Net margin | -31.0% | -40.7% | -77.8% | -116.2% | -173.6% |
| Revenue growth, year over year | +37.2% | +64.8% | +81.6% | +117.6% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 25, 2025 | Feb 27, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Cash and equivalents | $286.5M | $333.7M | $257.2M | $221.9M | $304.3M |
| Accounts receivable | $83.5M | $83.5M | $48.4M | $15.3M | $4.46M |
| Inventory | $70.7M | $56.2M | $39.8M | $28.5M | $13.1M |
| Total current assets | $450.4M | $481.8M | $350.6M | $272.6M | $326.2M |
| Property, plant and equipment | $30.4M | $26.7M | $28.7M | $8.66M | $5.04M |
| Total assets | $508.1M | $534.0M | $404.7M | $309.3M | $337.0M |
| Accounts payable | $17.3M | $10.0M | $13.5M | $9.39M | $2.03M |
| Short-term debt | – | – | – | – | $0 |
| Total current liabilities | $65.8M | $53.1M | $45.9M | $35.3M | $16.2M |
| Long-term debt | $51.6M | $51.5M | $51.3M | $51.2M | $50.0M |
| Total liabilities | $142.2M | $131.8M | $124.0M | $112.3M | $69.9M |
| Shareholders' equity | $365.9M | $402.2M | $280.8M | $197.1M | $267.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Feb 25, 2025 | Feb 27, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Operating cash flow | -$49.0M | -$99.2M | -$108.0M | -$80.4M | -$57.3M |
| Capital expenditures | $9.36M | $4.41M | $25.2M | $2.65M | $592.0K |
| Free cash flow | -$58.3M | -$103.6M | -$133.2M | -$83.0M | -$57.9M |
| Depreciation and amortization | $6.39M | $5.23M | $3.81M | $2.84M | $3.32M |
| Stock-based compensation | $47.6M | $31.8M | $19.1M | $10.3M | $3.80M |
| Investing cash flow | -$9.36M | -$4.41M | -$25.2M | -$2.65M | -$592.0K |
| Financing cash flow | $11.2M | $180.1M | $167.8M | $3.61M | $262.1M |
| Net change in cash | -$47.2M | $76.5M | $34.6M | -$79.4M | $204.2M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 15.5% | 14.2% | 14.0% | 13.8% | 11.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 29, 2026 | 57.5M | +3.0% | SEC |
| Jul 31, 2026 | 57.3M | +2.9% | SEC |
| Apr 24, 2026 | 56.9M | +2.9% | SEC |
| Feb 19, 2026 | 56.4M | +2.9% | SEC |
| Oct 29, 2025 | 55.9M | +7.1% | SEC |
| Jul 31, 2025 | 55.6M | +7.1% | SEC |
| Apr 25, 2025 | 55.3M | +7.6% | SEC |
| Feb 20, 2025 | 54.8M | +7.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.